EFG vs IVIG in TAMG

Prior treatment

• Patients with weight loss of more than 5kg in the past month; severe uncontrolled systemic disease, such as active infection or poorly controlled diabetes; patients with hemorrhagic diseases and bleeding tendencies; coagulation dysfunction, bleeding tendency or receiving thrombolytic or anticoagulant therapy; patients with grade II-IV bone marrow suppression;
• Received biological agents such as rituximab or ibritumomab tiuxetan within 6 months; underwent plasma exchange within 1 month;
• Selective IgA deficiency with anti-IgA antibodies;

Other illness

• Confirmed history of congestive heart failure; poorly controlled angina pectoris with drug treatment; electrocardiogram (ECG) confirmed transmural myocardial infarction; poorly controlled hypertension; clinically significant valvular heart disease; or high-risk uncontrolled arrhythmia;
• History of organ transplantation (including autologous bone marrow transplantation and peripheral stem cell transplantation);
• Patients with peripheral nervous system disorders or significant mental disorders and a history of central nervous system disorders;
• Patients who cannot tolerate single-lung ventilation during surgery; severe cardiac complications, cardiovascular decompensation, patients with implanted cardiac pacemakers;
• Patients in the acute inflammatory period due to bacterial, viral or other microbial infections; known active infections of human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV), or known HIV seropositivity;
• Patients who have undergone thoracic surgery due to tuberculous pleurisy, mesothelioma, lung disease, or diaphragmatic disease, with ipsilateral lung atelectasis involving one lobe or more than one lobe;
• Thrombosis, renal impairment or renal failure;
• Allergic to human immunoglobulin or have other severe allergic history;

Lab values

• Females with positive serum pregnancy test or in lactation period, and males and females of childbearing age who are unwilling to use adequate contraceptive measures during treatment;
• Serum IgG level \<4.5 g/L;
• Subjects with impaired function of major organs, abnormal blood routine, lung, liver, kidney and cardiac function, and the following laboratory test results:
  • Blood: white blood cells \<4.0×10\^9/L, absolute neutrophil count (ANC) \<2.0×10\^9/L, platelet count \<100×10\^9/L, hemoglobin \<90g/L; Liver function: serum bilirubin \>1.5 times the upper normal limit; ALT and AST \>1.5 times the upper normal limit; Renal function: serum creatinine (SCr) \>120 μmol/L, creatinine clearance rate (CCr) \<60 ml/min;

Other

• MGFA type V;
• Patients who have undergone median sternotomy;
• Patients participating in other clinical studies simultaneously;

• Patients aged \>18 years and ≤75 years, with an expected survival time \>12 months;
• Patients with generalized myasthenia gravis;
• MG-ADL ≥6;
• Positive for AChR antibody;
• Diagnosed with thymoma by enhanced chest CT or MRI;
• Patients with thymoma combined with myasthenia gravis who are diagnosed by MDT and need to undergo thymectomy;
• Patients with American Society of Anesthesiologists (ASA) grade 1-2;
• Able to understand the study situation and sign the Informed Consent.